Fig. 3From: Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort studyLocation of missense mutations mapped onto the protein structure of ABL kinase domain. Blue indicates location of mutations A344V, E355A, K357T, and E453K; red indicates location of clinically resistant mutations; yellow indicates location of imatinibBack to article page